Renal denervation for treatment of arterial hypertension – the unanswered questions

Česká verzia

Authors: Jitka Seidlerová ^1,3; Jiří Koza ^2,3; Ivo Bernat ^2,3; Richard Rokyta ^2,3; Vratislav Pechman ^2,3; Jan Filipovský ^1,3
Authors place of work: Centrum pro výzkum a léčbu arteriální hypertenze, II. interní klinika LF UK v Plzni a FN Plzeň, přednosta prof. MUDr. Jan Filipovský, CSc. ¹; Kardiologické oddělení FN Plzeň, přednosta prof. MUDr. Richard Rokyta, Ph. D. ²; Komplexní kardiovaskulární centrum FN Plzeň ³
Published in the journal: Vnitř Lék 2014; 60(2): 134-138
Category: Review

Summary

Despite the extensive armamentarium of antihypertensive medication available, the control of hypertension remains poor. Therefore any possibilities of non-pharmacological treatment of resistant hypertension are welcome. Recently, close attention was paid to renal denervation. Present work summarizes the scientific reports and clinical trials related to this topic published so far and addresses the unanswered questions. Moreover, it also contains brief summary of authors’ own experience with the method.

Key words:
renal denervation – resistant hypertension – sympathetic nervous system

Zdroje

1. Cífková R, Bruthans J, Adámková V et al. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006–2009. Studie Czech post-MONICA. Cor et Vasa 2011; 53(4–5): 220–229.

2. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281–1357.

3. de la Sierra A, Segura J, Banegas JR et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57(5): 898–902.

4. Schlaich MP, Lambert E, Kaye DM et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 2004; 43(2): 169–175.

5. Schlaich MP, Sobotka PA, Krum H et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361(9): 932–934.

6. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373(9671): 1275–1281.

7. Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376(9756): 1903–1909.

8. Esler MD, Krum H, Schlaich M et al. Renal sympathetic denervation for treatment of drug-resistant hypertension. One-year results from the SYMPLICITY HTN-2 randomized controlled trial. Circulation 2012; 126(25): 2976–2982.

9. SYMPLICITY HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57(5): 911–917.

10. Worthley SG, Tsioufis CP, Worthley MI et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 2013; 34(28): 2132–2140.

11. Filipovský J, Widimský jr. J, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58(10): 785–801.

12. Ceral J, Habrdová V, Voříšek V et al. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res 2011; 34(1): 87–90.

13. Sherrill B, Halpern M, Khan S et al. Single-pill vs. free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens 2011; 13(12): 898–909.

14. Jung O, Gechter JL, Wunder C et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31(4): 766–774.

15. Hansen TW, Kikuya M, Thijs L et al. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. J Hypertens 2007; 25(8): 1554–1564.

16. Staessen JA, Thijs L, Ohkubo T et al. Thirty years of research on diagnostic and therapeutic thresholds for the self-measured blood pressure at home. Blood Press Monit 2008; 13(6): 352–365.

17. Templin C, Jaguszewski M, Ghadri JR et al. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity® catheter system and the EnligHTNTM multi-electrode renal denervation catheter. Eur Heart J 2013; 34(28): 2141–2148.

18. Steigerwald K, Titova A, Malle C et al. Morphological assessment of renal arteries after radiofrequency catheter-based sympathetic denervation in a porcine model. J Hypertens 2012; 30(11): 2230–2239.

19. Rippy MK, Zarins D, Barman NC et al. Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin Res Cardiol 2011; 100(12): 1095–1101.

20. Brinkmann J, Heusser K, Schmidt BM et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity indifficult-to-control hypertensive patients: prospective case series. Hypertens 2012; 60(6): 1485–1490.

21. Widimský P, Filipovský J, Widimský jr. J et al. Odborné stanovisko České kardiologické společnosti a České společnosti pro hypertenzi k provádění katetrizačních renálních denervací (RDN) v České republice. Cor et Vasa 2012; 54(3–4): 155–159.

22. Persu A, Renkin J, Thijs L et al. Renal Denervation: Ultima ratio or standard in treatment-resistant hypertension. Hypertens 2012; 60(3): 596–606.

23. Kandzari DE, Bhatt DL, Sobotka PA et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012; 35(9): 528–535.